TFRC and cancer: Although several studies have reported that HFn could be used as a drug carrier for targeted drug delivery to cancer cells [15, 17, 19, 23], there are no reports on the differences in the expression levels of the HFn receptor TFRC in the target cells before and after treatment, which will have an important impact on the efficiency of drug delivery achieved by targeted drug delivery systems based on HFn nanocages.